<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559348</url>
  </required_header>
  <id_info>
    <org_study_id>T1217</org_study_id>
    <nct_id>NCT03559348</nct_id>
  </id_info>
  <brief_title>Locally Advanced or Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase II Trial of Biweekly S-1, Leucovorin and Gemcitabine in Elderly Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple centers, uncontrolled, open-label, non-randomized single-arm study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the following items in patients with metastatic pancreatic adenocarcinoma&#xD;
      receiving GSL treatment, Primary objective: Overall tumor response rate (by RECIST criteria)&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Disease control rate (Objective response rate + stable disease â‰§ 16 weeks) Time to tumor&#xD;
      progression Progression-free survival Overall survival Clinical benefit response Quality of&#xD;
      life Safety profile Biomarker of pancreatic cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>we assume 3.7 months as the PFS0, and 5.0 months as the PFS1 for this trial regimen (GSL).</time_frame>
    <description>The progression-free survival time for elderly patients with advanced pancreatic cancer receiving gemcitabine alone in randomized clinical trials were 3.3 - 3.7 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall tumor response rate</measure>
    <time_frame>It is anticipated that 18 months may be required to enroll the 88 patients in phase II trial.</time_frame>
    <description>the target number of patients will be 88 (with 10% dropout rate) if the expected follow-up time for each patient is 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Biweekly TS-1, Leucovorin and Gemcitabine (GSL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy: TS-1, Leucovorin and Gemcitabine</intervention_name>
    <description>Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.</description>
    <arm_group_label>Biweekly TS-1, Leucovorin and Gemcitabine (GSL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have cyto-/histologically confirmed, recurrent or metastatic&#xD;
             adenocarcinoma of the pancreas.&#xD;
&#xD;
          2. Patients have disease measurable or evaluable on x-ray, computed tomography scan, or&#xD;
             physical examination.&#xD;
&#xD;
          3. Patients have no history of prior chemotherapy for metastatic pancreatic cancer.&#xD;
             Patients who had received chemotherapy as in an adjuvant or neoadjuvant setting which&#xD;
             was completed at least 6 months before recurrence are eligible.&#xD;
&#xD;
          4. Patients with prior radiotherapy are eligible if the irradiated area does not involve&#xD;
             the only lesion of measurable / evaluable disease.&#xD;
&#xD;
          5. Baseline ECOG performance status is 2.&#xD;
&#xD;
          6. Patients have life expectancy of at least 12 weeks.&#xD;
&#xD;
          7. Patients have age 70 years.&#xD;
&#xD;
          8. Patients have adequate organ function.&#xD;
&#xD;
          9. Patients with biliary obstruction which is adequate drained before enrollment are&#xD;
             eligible.&#xD;
&#xD;
         10. Patients agree to have an indwelling venous catheter implanted.&#xD;
&#xD;
         11. Women or men of reproductive potential should agree to use an effective contraceptive&#xD;
             method.&#xD;
&#xD;
         12. All patients must be informed of the investigational nature of this study and must&#xD;
             sign written informed consents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have major abdominal surgery, radiotherapy or other investigating agents&#xD;
             within 4 weeks are not eligible. Patients who have palliative radiotherapy for bony&#xD;
             metastasis will be eligible if the irradiated area does not involve the only lesion of&#xD;
             measurable / evaluable disease.&#xD;
&#xD;
          2. Patients with metastatic lesion in central nervous system.&#xD;
&#xD;
          3. Patients with active infection.&#xD;
&#xD;
          4. Patients with active cardiopulmonary disease or history of ischemic heart disease.&#xD;
&#xD;
          5. Patients who have peripheral neuropathy &gt; grade I of any etiology.&#xD;
&#xD;
          6. Patients who have serious concomitant systemic disorders incompatible with the study,&#xD;
             i.e. poorly controlled diabetes mellitus, auto-immune disorders, cirrhosis of the&#xD;
             liver, and the rest will be at the discretion of in-charged investigator.&#xD;
&#xD;
          7. Patients who have other prior or concurrent malignancy except for adequately treated&#xD;
             in situ carcinoma of cervix or adequately.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in Elderly Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

